# Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

> **NCT02431806** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 552 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Levomilnacipran
- **DRUG:** Fluoxetine

## Key facts

- **NCT ID:** NCT02431806
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2020-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431806, "Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02431806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*